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Abstract
Introduction:  Angelman  syndrome  is  characterized  by  severe  mental  retardation  and  speech
and seizure  disorders.  This  rare  genetic  condition  is  associated  with  changes  in  GABAA receptor.
Patients with  Angelman  syndrome  need  to  be  sedated  during  an  electroencephalogram  ordered
for diagnostic  purposes  or  evolutionary  control.  Dexmedetomidine,  whose  action  is  indepen-
dent of  GABA  receptor,  promotes  a  sleep  similar  to  physiological  sleep  and  can  facilitate  the
performing of  this  examination  in  patients  with  Angelman  syndrome.
Case report: Female  patient,  14  years  old,  with  Angelman  syndrome;  electroencephalogram
done under  sedation  with  dexmedetomidine.  The  procedure  was  uneventful  and  bradycardia
or respiratory  depression  was  not  recorded.  The  examination  was  successfully  interpreted  and
epileptiform  activity  was  not  observed.
Conclusion:  Dexmedetomidine  promoted  satisfactory  sedation,  was  well  tolerated  and  enabled
the interpretation  of  the  electroencephalogram  in  a  patient  with  Angelman  syndrome  and
seizure disorder.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
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Síndrome  de
Sedac¸ão com  dexmedetomidina  para  realizac¸ão  de  eletroencefalograma  em  paciente
portadora  de  síndrome  de  Angelmann:  relato  de  casoAngelman;
Eletroencefalograma; Resumo
 Angelman  (SA)  é  caracterizada  por  retardo  mental  grave,  dis-
m  convulsiva.  Essa  condic¸ão  genética  rara  está  associada  a
AA.  Pacientes  portadores  de  SA  necessitam  ser  sedados  durante
alograma  (EEG),  indicado  para  ﬁns  diagnósticos  ou  controleSedac¸ão profunda;
Dexmedetomidina
Introduc¸ão:  A  síndrome  de
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evolutivo.  A  dexmedetomidina,  cuja  ac¸ão  independe  do  receptor  GABA,  promove  sono  semel-
hante ao  ﬁsiológico  e  pode  viabilizar  a  feitura  desse  exame  em  pacientes  com  SA.
Relato de  caso:  Paciente  feminina,  14  anos,  portadora  de  SA,  fez  EEG  sob  sedac¸ão  com
dexmedetomidina.  O  procedimento  transcorreu  sem  intercorrências  e  não  foi  registrada
bradicardia  ou  depressão  respiratória.  O  exame  foi  interpretado  com  sucesso  e  atividade  epilep-
tiforme não  foi  observada.
Conclusão:  A  dexmedetomidina  promoveu  sedac¸ão  satisfatória,  foi  bem  tolerada  e  possibilitou
a interpretac¸ão  do  EEG  em  paciente  com  SA  e  desordem  convulsiva.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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Patients  with  genetic  disorders,  common  or  not,  with  or
without  congenital  abnormalities,  present  unique  chal-
lenges  for  the  professional  responsible  for  administering
sedation  or  anaesthesia  during  surgical  or  technical
procedures.  Angelman  syndrome  (AS)  is  a  clear  example  of
this  situation,  which  requires  special  care  because  of  the
increased  risk  of  complications.1 Patients  with  AS  exhibit
convulsive  disorder,  make  regular  use  of  anticonvulsants  and
depend  on  electroencephalogram  (EEG)  studies  for  diagnosis
or  evolutionary  control.  However,  because  of  the  changing
behaviour,  common  to  many  other  neurological  conditions,
the  sedation  during  EEG  is  often  necessary.  This  is  pecu-
liar  because  the  sedatives  and  hypnotics  commonly  used  in
anaesthesia  interfere  with  EEG  basal  patterns,2 wrecking  its
use  during  the  examination.  In  addition,  in  AS  patients  some
genetic  characteristics  related  to  acid  gamma-aminobutyric
acid  type  A  (GABAA)  are  observed,3 and  GABAA is  a  target
for  some  sedatives  and  hypnotics.  The  aim  of  this  report  is
to  discuss  the  use  of  dexmedetomidine  for  sedation  during
EEG,  focusing  on  the  unique  aspects  of  AS.
Case report
The  case  is  of  a  female  patient,  14  years  old,  43  kg,
diagnosed  with  AS,  with  seizures,  in  regular  use  of  pheno-
barbital,  reporting  bronchial  asthma  and  kyphoscoliosis  and
using  thoracocervical  vest.  Laboratory  tests  and  preoper-
ative  electrocardiogram  were  normal.  In  the  examination
room,  the  patient  was  monitored  with  ECG,  pulse  oximetry
and  non-invasive  measurement  of  blood  pressure.  Peripheral
intravenous  access  was  obtained  to  allow  dexmedeto-
midine  infusion  (bolus  of  1  g  kg--1 and  maintained  with
0.05--0.2  g  kg  h--1).  The  patient  remained  relatively  stable
during  the  procedure.  There  was  a  moderate  decrease  in
mean  arterial  pressure  (MAP)  during  infusion  of  the  initial
dose,  when  this  parameter  ranged  from  59  to  40  mmHg.  The
heart  rate  ranged  from  80  to  85  bpm  and  no  bradycardia
was  observed.  This  patient  had  an  episode  of  upper  airway
obstruction,  corrected  with  an  oropharyngeal  cannula;  but
the  oxygen  saturation  remained  above  92%  without  supple-
mental  oxygen.  The  dexmedetomidine  doses  were  adjusted
according  to  the  level  of  sedation  and  haemodynamic  effects
and  there  was  no  spontaneous  movement  during  the  20-
min  recording  of  the  EEG.  The  patient  awoke  spontaneously
20  min  after  the  end  of  the  test  and  was  released  from  the
s
a
o
cnit  after  90  min.  The  analysis  of  EEG  was  performed  by
 neurologist  who  found  stages  I  and  II  of  NREM  sleep  and
bsence  of  epileptiform  potentials.
iscussion
f  rare  incidence,  estimated  at  1/10,000--1/40,000,4 AS  was
rst  described  by  Harry  Angelman  in  1965.5 This  clinical
yndrome  includes  a  neurodevelopmental  disorder  charac-
erized  by  severe  learning  difﬁculties,  ataxia,  seizures,  and
ysmorphic  facial  features.  The  sociable  and  happy  facial
xpression  motivated  the  initial  designation  of  ‘‘puppet
hild’’.  Most  children  have  developmental  delay  and  growth
etardation  of  the  head  during  the  ﬁrst  year  of  life.  Speech
oes  not  develop  in  most  patients.  AS  is  caused  by  a  variety
f  genetic  abnormalities  that  include  chromosomal  region
5q11-13,  a  segment  responsible  for  encoding  the  gamma
ubunit  of  GABAA receptor.6
Some  relevant  points  are  worth  mentioning  in  relation  to
he  particularities  of  sedation  for  EEG  in  patients  with  AS.
he  ﬁrst  one  includes  common  anaesthetic  problems  such
s  those  arising  from  anatomical  changes  or  haemodynamic
esponses.  Craniofacial  abnormalities,  including  micro-
ephaly,  deep-set  eyes,  high  arched  palate  and  tongue
rotrusion,3 may  pose  problems  in  the  management  of  air-
ay  and  in  tracheal  intubation.  In  this  patient,  upper  airway
bstruction  associated  with  macroglossia  was  corrected  with
n  oropharyngeal  airway,  but  respiratory  depression  was  not
ound  and  not  even  ventilation  under  mask  was  required.
egardless,  all  support  for  difﬁcult  airways  approach  was
vailable,  because  asthma,  kyphoscoliosis  and  the  use  of
 thoracocervical  vest  represent  aggravating  factors  for
omplications,  if  a more  invasive  approach  to  the  airway
as  needed.  Bradycardia  related  to  vagal  predominance,
mphasized  in  other  previous  reports,7 was  not  reported
uring  the  infusion  of  dexmedetomidine.  In  contrast,  moder-
te  hypotension  was  observed,  but  without  need  of  speciﬁc
ntervention.
The  second  point  refers  to  changes  in  GABAA receptor,
iven  its  importance  as  a  target  of  action  of  drugs  com-
only  used  for  sedation  and  anaesthesia,3 such  as  propofol.
espite  the  relevance  of  this  aspect,  clinical  information  on
he  effects  of  such  drugs  in  this  special  group  of  patients  is
carce  and  not  fully  understood.  It  is  estimated  that  a  vari-
tion  in  clinical  response  or  even  a  resistance  to  such  drugs
ccurs,  which  is  why  some  authors  suggest  that  their  asso-
iation  with  other  drugs  acting  on  different  pathways  would
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e  a  good  strategy  for  sedation  and/or  general  anaesthesia.7
herefore,  dexmedetomidine,  whose  target  of  action  is  the
2 receptor,  would  represent  an  option,  not  only  as  a sin-
le  agent,  but  also  as  an  adjunct  to  general  anaesthesia  or
edation.
The  last  relevant  aspect  is  the  interpretation  of  EEG,
onsidering  the  possible  interferences  in  its  basal  pattern,
esulting  from  the  administration  of  various  anaesthet-
cs  and  sedatives,  including  propofol,  benzodiazepines  and
nhaled  anaesthetics.  Even  chloral  hydrate,  which  is  tradi-
ionally  used  for  this  purpose,2 can  interfere  with  the  EEG
attern,8 besides  showing  sedation  failure  in  27%  of  patients
ith  behaviour  change.9 In  the  present  report,  although
he  electroencephalographic  changes  commonly  seen  in  AS4
ave  not  been  observed,  the  analysis  of  this  examination
as  successfully  done  and  favoured  the  clinical  control.
For  all  the  reasons  cited,  dexmedetomidine  emerges  as
 promising  resource  for  patients  with  AS,  especially  those
andidates  who  undergo  EEG  under  sedation.  Being  a  highly
elective  ˛2 adrenergic  agonist,  this  drug  has  a  mechanism
f  action  independent  of  GABA  receptor,  promoting  seda-
ion  very  similar  to  the  physiological  sleep,  with  minimal
espiratory  depression.  It  also  has  antipruritic,  antiemetic,
nalgesic  and  sympatholytic  properties.  Dexmedetomidine
perates  in  several  locations  in  the  central  nervous  system,
ut  its  sedative  and  anxiolytic  effects  result  mainly  from
ts  activity  in  the  locus  coeruleus  of  the  brainstem.  In  the
orsal  horn  of  the  spinal  cord,  it  modulates  the  release  of
ubstance  P  and  produces  its  analgesic  effects.  The  sedation
s  accompanied  by  minimal  effects  on  respiratory  function.10
n  adult  volunteers,  no  interference  at  EEG  basal  pattern
as  observed,  and  the  sleep  induced  by  dexmedetomidine
ompared  with  the  natural  sleep.11 Considering  that  these
esults  also  apply  to  patients  with  epilepsy  and  behaviour
hanges,  this  drug  tends  to  set  itself  up  as  a  good  choice  for
edation  during  EEG.  Some  retrospective  studies  point  to  the
fﬁcacy  and  safety  of  this  drug  for  sedation  for  further  exam-
nations,  including  EEG,12,13 although  no  prospective  studies
ave  been  published  evaluating  the  possible  interference  of
exmedetomidine  on  EEG  in  special  patients.
Therefore,  despite  all  limitations,  this  report  high-
ights  the  good  tolerance  and  adequate  sedation  promoted
y  dexmedetomidine,  which  enabled  the  recording  and
nterpretation  of  EEG  in  our  patient.  Despite  the  little
vidence,  this  drug  may  represent  an  option  for  sedation
1M.L.  Fernandes  et  al.
uring  this  diagnostic  procedure  in  patients  with  chronic
eurological  disorders  and  behaviour  modiﬁcation,  includ-
ng  those  patients  with  AS.  However,  prospective  controlled
rials  that  speciﬁcally  emphasize  the  effects  of  the  drug  on
EG  are  needed  to  conﬁrm  these  beneﬁts.
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